Curated News
By: NewsRamp Editorial Staff
August 17, 2026
Helix BioPharma Appoints Dr. Markus Loeffler as Chief Medical Officer
TLDR
- Helix BioPharma's new CMO brings 30+ years of oncology expertise, likely accelerating clinical progress and boosting investor confidence.
- Markus Loeffler will lead clinical strategy for L-DOS47's Phase Ib/II trial and advance LEUMUNA toward IND, leveraging his experience in pivotal trials.
- This appointment aims to develop new treatments for difficult-to-treat cancers, offering hope to patients with limited options.
- Dr. Loeffler previously led the Phase III program for Lutathera, a targeted cancer therapy that received FDA approval.
Impact - Why it Matters
This appointment is pivotal for Helix BioPharma as it signals a strategic move to accelerate its clinical programs. Dr. Loeffler's extensive experience in oncology drug development, particularly his success with Lutathera, brings credibility and expertise that could enhance the company's ability to navigate regulatory pathways and bring innovative therapies to market. For patients with difficult-to-treat cancers, this could mean faster access to potential new treatments like L-DOS47 for NSCLC and LEUMUNA for post-transplant leukemia relapse. For investors, it indicates a strengthened leadership team focused on execution, potentially improving the company's prospects for clinical and commercial success.
Summary
VANCOUVER, BC - August 17, 2026 (NEWMEDIAWIRE) - Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCF, FRANKFURT: HBP0), a clinical-stage oncology company focused on developing therapies for difficult-to-treat cancers, has announced the appointment of Markus Loeffler, MD, MBA, as its new Chief Medical Officer (CMO). Dr. Loeffler brings over three decades of leadership in oncology drug development, having held senior roles at Roche, Advanced Accelerator Applications, Mundipharma, NH TherAguix, Corbus Pharmaceuticals, and SK Life Science. Notably, he led the pivotal Phase III clinical program for Lutathera, a radiopharmaceutical approved for certain neuroendocrine tumors. His expertise spans small molecules, biologics, antibody-drug conjugates, and immunotherapies, from early-stage development to regulatory approval.
As Helix prepares to enter a more execution-focused phase, Dr. Loeffler will lead the strategy and execution of clinical programs, including the planned Phase Ib/II evaluation of L-DOS47 in combination with pembrolizumab for first-line non-small cell lung cancer (NSCLC). He will also guide LEUMUNA, a pre-IND oral immune checkpoint modulator, toward clinical development for leukemia relapse following allogeneic stem cell transplantation. CEO Thomas Mehrling, MD, PhD, expressed confidence in Dr. Loeffler's ability to translate innovative science into well-executed clinical programs. Dr. Loeffler's appointment comes as the company advances its pipeline, which also includes GEMCEDA, a pre-IND gemcitabine prodrug for advanced solid tumors. The company's shares are listed on the Toronto Stock Exchange, OTC Pink Market, and Frankfurt Stock Exchange. For more information, visit the company's website at https://www.helixbiopharma.com/.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Helix BioPharma Appoints Dr. Markus Loeffler as Chief Medical Officer
